A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study With a Lead in Phase of Erlotinib With or Without SNDX-275 in Patients With Non-small Cell Lung Carcinoma After Failure In Up to Two Prior Chemotherapeutic Regimens for Advanced Disease.

Trial Profile

A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study With a Lead in Phase of Erlotinib With or Without SNDX-275 in Patients With Non-small Cell Lung Carcinoma After Failure In Up to Two Prior Chemotherapeutic Regimens for Advanced Disease.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 Apr 2012

At a glance

  • Drugs Entinostat (Primary) ; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms ENCORE-401
  • Most Recent Events

    • 30 Apr 2012 Results have been published in the Journal of Clinical Oncology according to a Syndax Pharmaceuticals media release.
    • 18 Apr 2012 Actual end date (Mar 2012) added as reported by ClinicalTrials.gov.
    • 07 Jul 2011 Biomarker analysis presented at the 14th Annual Congress of the European Respiratory Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top